Aradigm Corporation, Hayward, California, USA.
Department of Biomedical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, Oregon, USA.
Antimicrob Agents Chemother. 2018 Sep 24;62(10). doi: 10.1128/AAC.00440-18. Print 2018 Oct.
Nontuberculous mycobacteria (NTM) affect an increasing number of individuals worldwide. Infection with these organisms is more common in patients with chronic lung conditions, and treatment is challenging. Quinolones, such as ciprofloxacin, have been used to treat patients, but the results have not been encouraging. In this report, we evaluate novel formulations of liposome-encapsulated ciprofloxacin (liposomal ciprofloxacin) and Its efficacy against and was examined in macrophages, in biofilms, and using intranasal instillation mouse models. Liposomal ciprofloxacin was significantly more active than free ciprofloxacin against both pathogens in macrophages and biofilms. When evaluated , treatment with the liposomal ciprofloxacin formulations was associated with significant decreases in the bacterial loads in the lungs of animals infected with and In summary, topical delivery of liposomal ciprofloxacin in the lung at concentrations greater than those achieved in the serum can be effective in the treatment of NTM, and further evaluation is warranted.
非结核分枝杆菌（NTM）在全球范围内影响着越来越多的人群。感染这些病原体的患者通常患有慢性肺部疾病，且治疗极具挑战性。喹诺酮类药物（如环丙沙星）已被用于治疗此类患者，但收效甚微。在本报告中，我们评估了脂质体包封环丙沙星（脂质体环丙沙星）的新配方，并在巨噬细胞、生物膜中和通过鼻腔内滴注的小鼠模型中检测了其对两种病原体的疗效。脂质体环丙沙星对巨噬细胞和生物膜中的两种病原体均比游离环丙沙星具有更高的活性。在评估时，脂质体环丙沙星制剂的治疗与感染 和 的动物肺部细菌载量的显著降低相关。总之，在肺部给予高于血清中可达到浓度的脂质体环丙沙星的局部递送可能是治疗 NTM 的有效方法，值得进一步评估。
